Stefan Lentrodt1, Jürgen Lentrodt, Norbert Kübler, Ulrich Mödder. 1. Hyperbaric Oxygen Unit, Institute of Diagnostic Radiology, Institute of Diagnostic Radiology and the Clinic of Maxillofacial Plastic Surgery, Westdeutsche Kieferklinik, University Hospital Düsseldorf, Düsseldorf, Germany. lentrodt@t-online.de
Abstract
PURPOSE: In this article, the question of whether adjuvant hyperbaric oxygen therapy (HBO) has a positive effect when treating chronically recurrent mandibular osteomyelitis in children and adolescents is discussed. PATIENTS AND METHODS: Over a period of 5 years, 4 cases were observed, 3 of which were submitted to adjuvant HBO. Details on the modalities of this type of treatment and the simultaneous intravenous administration of high doses of antibiotics are reported. RESULTS: All 3 patients have been free of any symptoms from 20 to 74 months (mean, 41 months) and therefore may most likely be regarded as healed. CONCLUSION: The small number of cases does not allow a final statement on the extent to which HBO contributed to the positive outcome. However, in our opinion, HBO is a most promising therapeutic option. Finally, the problems involved in prospective randomized studies of this rare disease are discussed in detail.
PURPOSE: In this article, the question of whether adjuvant hyperbaric oxygen therapy (HBO) has a positive effect when treating chronically recurrent mandibular osteomyelitis in children and adolescents is discussed. PATIENTS AND METHODS: Over a period of 5 years, 4 cases were observed, 3 of which were submitted to adjuvant HBO. Details on the modalities of this type of treatment and the simultaneous intravenous administration of high doses of antibiotics are reported. RESULTS: All 3 patients have been free of any symptoms from 20 to 74 months (mean, 41 months) and therefore may most likely be regarded as healed. CONCLUSION: The small number of cases does not allow a final statement on the extent to which HBO contributed to the positive outcome. However, in our opinion, HBO is a most promising therapeutic option. Finally, the problems involved in prospective randomized studies of this rare disease are discussed in detail.